Entero Therapeutics, Inc.

NasdaqCM:ENTO Stock Report

Market Cap: US$2.9m

Entero Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:ENTO Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
09 Oct 24SellUS$212Sarah RomanoIndividual476US$0.45
02 Jul 24SellUS$1,379James SapirsteinIndividual1,289US$1.07
02 Jul 24SellUS$664Sarah RomanoIndividual621US$1.07
01 Apr 24SellUS$317Sarah RomanoIndividual75US$4.23
01 Apr 24SellUS$736James SapirsteinIndividual174US$4.23
15 Mar 24SellUS$5,555Sarah RomanoIndividual1,120US$4.96
15 Mar 24SellUS$9,360James SapirsteinIndividual1,887US$4.96
12 Jan 24SellUS$697James SapirsteinIndividual166US$4.20
12 Jan 24SellUS$412Sarah RomanoIndividual98US$4.20

Insider Trading Volume

Insider Buying: ENTO insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of ENTO?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders69,6851.47%
Institutions97,9222.06%
General Public4,586,42396.5%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 604.3%.

Top Shareholders

Top 18 shareholders own 3.53% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
0.75%
James Sapirstein
35,816US$22.2k0%no data
0.68%
Virtu Financial LLC, Asset Management Arm
32,190US$20.0k0%no data
0.56%
Two Sigma Securities, LLC, Asset Management Arm
26,612US$16.5k0%no data
0.38%
Sarah Romano
18,014US$11.2k-2.57%no data
0.34%
Geode Capital Management, LLC
16,055US$10.0k-0.56%no data
0.32%
Jack Syage
15,400US$9.5k0%no data
0.21%
Citadel Advisors LLC
10,052US$6.2k0%no data
0.16%
Tower Research Capital Europe Limited
7,484US$4.6k36.5%no data
0.095%
The Vanguard Group, Inc.
4,535US$2.8k0%no data
0.02%
Strategic Advisers LLC
965US$598.30%no data
0.0093%
Chaitan Khosla
440US$272.90%no data
0.00055%
Bank of America Corporation, Asset Management Arm
26US$16.218.2%no data
0.00021%
Edward Borkowski
10US$6.20%no data
0.00006%
Alastair Riddell
3US$1.80%no data
0.00004%
Charles Casamento
2US$1.20%no data
0.00002%
U.S. Bancorp Asset Management, Inc.
1US$0.60%no data
0.00002%
UBS Asset Management AG
1US$0.6-99.8%no data
0.00002%
Kathleen S. Wright Associates Inc.
1US$0.60%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 20:21
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Entero Therapeutics, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullArgus Research Company
Jonathan AschoffB. Riley Wealth
Leland GershellOppenheimer & Co. Inc.